CTLA4 and neoplasm: Furthermore, analysis using the TIMSO database revealed that ITGA4 could predict immunotherapy response in eight in vivo tumor killing assays (primarily involving anti-PD1, anti-CTLA4, and their combination, as well as anti-PDL1 and anti-PDL2) and three in vitro cytokine (primarily IFNg) killing assays (Figures 6F, G).